PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Quin is a mobile medical app that combines daily life experience with data from diabetes devices and phones and helps people decide how much insulin to take and when. They are on a mission to help people with insulin-treated diabetes make the best possible decisions through their app. The company have received a UK research and innovation grant. Apple has granted them insider access to their engineers and executives who are helping to get Quin to market, their app has a class I CE Mark, with two patents pending. With the investment, they will hire a product designer to enhance the user experience, achieve certification and compliance with new European Medical Device Regulations, develope B2B2C distribution partnerships and launch the Quin app in the UK and Europe in late 2020.
days to go:
Expired
investment:
£691,497
Please watch the video for more information
days to go:
Expired
investment:
£257,501
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.
days to go:
Expired
investment:
£211,595
SL'M is the world's first zero sugar, zero carb, zero fat range of wines which is approved by both the TSO and FSA. During COVID-19, the company witnessed record earnings, amidst profitable online sales in March 2020. The company has also been featured in publications such as Cosmopolitan, The Sun, and many more. Slim Wine's audience comprises Gen X, Millennials, and Boomers, giving the company a great cross-generational position in the market. The company has served over 2 million glasses of wine and generated profits of over £1 million amidst a growing customer base. Slim Wine's latest vintage, Cuvée 450, was showcased at the 'Royal Berkshire Polo Club'. The company will use the investment to boost sales and marketing, advertising campaigns, and wine production.
days to go:
Expired
investment:
£262,948
Northern Monk is a brewery. They started from their family home using other peoples breweries across Yorkshire and selling at farmers markets. In 2014 they found and restored a grade 2 listed building and turned it into a brewery, tap room and arts/events space and have added a second brewery close by. The investment will help them triple their capacity with 8 new 10,000 litre fermentation vessels and make production quicker, more efficient and reduce down time and waste with a new packaging line.
days to go:
Expired
investment:
£1,482,740
Swoopos is a mobile point of sale system, which brings together innovative software and hardware, cloud reporting and data analytics, mobile and ecommerce ordering and beacon marketing technology for retail, hospitality and stadiums. Swoops have already built long term relationships with leading brands and are now looking to expand throughout the UK and beyond.
days to go:
Expired
investment:
£64,480
PlusGuidance is an online counselling/therapy platform that gives people immediate access to counselling. It provides secure video, voice, IM and email sessions directly through the site, and booking in-person sessions too. Our Mission - Immediate access to counselling for everyone.Business Model - Software-as-a-Service for counsellors, who pay a monthly fee to use secure online sessions, practice management tools to manage their clients, and a public web profile in our directory.
days to go:
Expired
investment:
£115,022
